Drug Profile
Eribulin/encequidar - Athenex
Alternative Names: Encequidar/eribulin - Athenex; Eribulin + HM-30181A - Athenex; Eribulin ORA; Eribulin oral/encequidar oral - AthenexLatest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Athenex
- Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Benzopyrans; Cyclic ethers; Furans; Isoquinolines; Ketones; Macrocyclic compounds; Small molecules; Tetrazoles
- Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 12 Sep 2023 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO)
- 13 Feb 2023 Athenex terminates phase I trial in Solid Tumours in the US as per the sponsor decision(NCT04013217)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO, Liquid)